All In Biotech

Drug Trial Radar · NCT01492101

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine

Last checked: Nov 19, 2026Latest source record: Jun 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 852 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

852

Actual

Start

Dec 2011

Primary completion

Apr 2016

Study completion Jun 2016

Sponsor

Lead sponsor
Nektar TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.

Conditions

  • Locally Recurrent Breast Cancer
  • Metastatic Breast Cancer

Interventions

  • NKTR-102Drug

    145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.

  • Treatment of Physician's Choice (TPC)Drug

    One of the following Treatment of Physician Choice will be administered per standard of care: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Kaplan-Meier Estimate of Overall Survival: Intention to Treat (ITT) PopulationTime frame: 36 Months

Locations

153 sites in 11 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC - NAHOA

    Flagstaff, Arizona

  • Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center

    Burbank, California

  • University of Southern California

    Los Angeles, California

  • PMK Medical Group, Inc., DBA Ventura County Hematology Oncology Specialists

    Oxnard, California

  • Wilshire Oncology Medical Group, Inc.

    Pasadena, California

  • Desert Hematology Oncology Medical Group

    Rancho Mirage, California

  • University of California San Francisco

    San Francisco, California

  • Stanford University School of Medicine

    Stanford, California

  • Kaiser Permanente

    Vallejo, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Pre clinical Science Bldg LR3

    Washington D.C., District of Columbia

  • Medstar

    Washington D.C., District of Columbia

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • University of Miami School of Medicine

    Miami, Florida

  • Advanced Medical Specialties

    Miami, Florida

  • Florida Cancer Research Institute

    Plantation, Florida

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida

  • Northeast Georgia Cancer Care

    Athens, Georgia

  • Peachtree Hematology Oncology Consultants

    Atlanta, Georgia

  • Emory University

    Atlanta, Georgia

  • Central Georgia Cancer Care

    Macon, Georgia

  • Northwest Georgia Oncology Centers, P.C.

    Marietta, Georgia

  • Summit Cancer Care, P.C.

    Savannah, Georgia

  • The University of Chicago Medicine

    Chicago, Illinois

  • Oncology Specialists

    Niles, Illinois

  • Illinois Cancer Care, P.C.

    Peoria, Illinois

  • IU Health Simon Cancer Center

    Indianapolis, Indiana

  • Hall-Perrine Cancer Center, 3rd Floor

    Cedar Rapids, Iowa

  • Kansas City Cancer Center

    Overland Park, Kansas

  • Louisville Oncology Clinical Research Program

    Louisville, Kentucky

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland

  • Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Coborn Cancer Center

    Saint Cloud, Minnesota

  • Missouri Cancer Associates

    Columbia, Missouri

  • Washington University in St. Louis

    St Louis, Missouri

  • Missouri Baptist Medical Center

    St Louis, Missouri

  • Frontier Cancer Center and Blood Institute

    Billings, Montana

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.